相关实验视频
Updated: Jul 2, 2025

08:01
The Soft Agar Colony Formation Assay
Published on: October 27, 2014
111.7K
WAY-262611通过激活Wnt/β-catenin通路来改善炎症性肠病
Baiyinzi Du1,2, Shudan Luo3, Xujun Zhu1
1Shanghai Baoshan District Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai, China.
In vitro cellular & developmental biology. Animal
|February 23, 2024
概括
WAY-262611,是一种新的Dickkopf-1 (DKK-1) 抑制剂,通过激活Wnt/β-catenin通路来减轻炎症性肠病 (IBD). 这种治疗也减少了小鼠模型中的结直肠癌发病率.
科学领域:
- 胃肠病学 胃肠病学
- 细胞生物学 细胞生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- 炎症性肠病 (IBD) 涉及肠表皮损伤和修复,在其病变发生过程中至关重要.
- Wnt/β-catenin通路调节肠道干细胞的增殖和分化,并且受到Dickkopf-1 (DKK-1) 的负控制.
研究的目的:
- 在IBD小鼠模型中研究WAY-262611,一种新型DKK-1抑制剂的治疗潜力.
- 阐明WAY-262611对肠道炎症和上皮细胞的影响的机制.
主要方法:
- 使用DSS诱导IBD小鼠模型,分析Wnt3a和DKK-1表达.
- WAY-262611的疗效通过组织病理学评估,并对其在体外对Mode-k细胞活力和亡的影响进行了评估.
- 通过检测Wnt3a,DKK-1和核β-catenin转位,证实了Wnt/β-catenin通路的激活.
主要成果:
- 观察到Wnt3a和DKK-1表达之间的负相关性.
- WAY-262611显著改善了DSS诱导的IBD症状,并减少了Mode-k细胞亡.
- WAY-262611治疗激活了Wnt/β-catenin通路,并降低了正位直肠癌的发生率.
结论:
- WAY-262611通过激活Wnt/β-catenin通路来证明IBD的治疗潜力.
- 在IBD的背景下,WAY-262611也可能降低结直肠癌的风险.
更多相关视频
相关概念视频
Canonical Wnt Signaling Pathway
8.8K
The gene encoding the main signaling molecules of the Wnt signaling pathways (the Wnt proteins) was discovered almost four decades ago by Nüsslein-Volhard and Wieschaus. They identified and originally named the gene "wingless" (wg) after a phenotype discovered during their landmark genetic screen in Drosophila for body pattern defects. At around the same time, another researcher named Harold Varmus found that a murine tumor virus activates the mammalian wg homolog, Int-1, which...
8.8K
Role Of Notch Signalling In Intestinal Stem Cell Renewal
2.1K
Notch signaling was first discovered in Drosophila melanogaster, where it is involved in cell lineage differentiation. Notch signaling regulates the maintenance and differentiation of intestinal stem cells or ISCs by controlling the expression of atonal homolog 1 or Atoh1. Atoh1 directs cells to differentiate into secretory cells.
Direct cell-to-cell contact is needed for the activation of Notch signaling. The signal is initiated when a notch ligand binds to a receptor on an adjacent cell, also...
Direct cell-to-cell contact is needed for the activation of Notch signaling. The signal is initiated when a notch ligand binds to a receptor on an adjacent cell, also...
2.1K
Non-Canonical Wnt Signaling Pathways
7.3K
Wnt is a zygotic effect gene that is expressed during very early embryonic development. It regulates various processes in animals starting from early development through the adult stage, such as organogenesis in the embryo and maintenance of neuronal and blood stem cells. Wnt proteins can induce a wide variety of intracellular pathways depending upon the specific abilities of different Wnt ligands to form a complex with shared and cognate receptors in the presence of different co-receptors. The...
7.3K
Drugs for Treatment of Ulcerative Colitis in IBD
141
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
141
Inflammatory Bowel Disease IV: Pharmacological Management
127
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
127
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
163
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
163

